Significant advances in the therapy of extensive SCLC have occurred during the past two decades. The first major step involved the incorporation of active single agents into combination chemotherapeutic regimens, such as CAV. During the past decade the platinum compounds (cisplatin, carboplatin) and the epipodophylotoxins (etoposide, teniposide) also have been included in induction and salvage regimens for patients with SCLC. More recently, trials in previously untreated or minimally treated patients have revealed activity of several compounds such as ifosfamide and teniposide, as well as a potentially emerging role for chronic oral administration of etoposide. Numerous trials are currently being conducted by the HOG and others, and it is hoped that their results will elucidate the optimum role of ifosfamide and daily oral etoposide therapy in SCLC. Clearly, carefully designed prospective, randomised trials are necessary to weigh accurately potential benefits against the cost, morbidity, and mortality of treatments.
- Small cell lung cancer
ASJC Scopus subject areas